West Conshohocken’s Madrigal Pharmaceuticals earned a major win with the FDA approval of its first commercial product, reports John George for the Philadelphia Business Journal.
Rezdiffra, a treatment for NASH or nonalcoholic steatohepatitis, is the first therapy cleared for the U.S for this condition, which affects millions of Americans.
With the FDA’s green light, Madrigal is now shifting from a research-heavy biotech operation to a fully commercial pharmaceutical company. The transition comes with rapid growth. The company has added over 350 employees in recent months and expects to hit 500 by year’s end.
It’s also moved into a new West Conshohocken headquarters designed to support its expanding team.
Madrigal’s focus on liver and cardio-metabolic diseases has drawn investor attention as well. The company’s stock has climbed since the FDA approval, a strong sign of confidence in its new path forward.
Madrigal was founded in 2011 and is quickly becoming a Montco success story as it shapes the national conversation about liver disease treatment.
Read more about Madrigal Pharmaceuticals of West Conshohocken’s groundbreaking treatment for NASH in the Philadelphia Business Journal.
Editor’s Note: This post was originally published on MONTCO.Today in July 2025.
